
    
      The dose to use for this Intermediate- Size Patient Population Expanded Access Protocol is
      200 million HB-adMSCs, administered through intravenous infusion only, with a treatment
      duration of 14 weeks, infusion rate 4-5ml/min and total volume of 250 ml Sodium chloride
      0.9%. A total of 5 administrations and a dosing interval of two weeks for the first two
      HB-adMSCs administrations and one month after that.
    
  